Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Schofield

Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs.  As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Advertisement
Set Alert for Articles By Ian Schofield

Latest From Ian Schofield

Overplay Of Big Data Benefits Worries French Medical Experts

While big data has a place in drug regulation, it is important to avoid putting too much emphasis on its use in the post-authorization phase, say French medical journal editors in response to the report on big data from EU agency heads and the EMA.
Europe France

Cambodia's ‘Fragmented’ Regulatory Rules To Be Overhauled

Cambodia’s regulatory framework needs an overhaul, according to the World Health Organization, which has issued a tender for interested parties to review the current situation and produce draft legislation that meets current international norms.

Cambodia Regulation

Overhaul In Store For Cambodia's ‘Fragmented’ Drug Rules

Cambodia’s drug regulatory framework needs an overhaul, according to the World Health Organization, which has issued a tender for interested parties to review the current situation and produce draft legislation that meets current international norms.
Cambodia Regulation

Italy’s Little-Known Early Access Program

Italy’s early access system is mainly used for unapproved uses of authorized medicines, and is driven by clinicians, rather than companies.

Reimbursement Italy

Biosimilar Interchangeability Policies Need Closer Alignment

Regulators should take more of a role in decisions on biosimilar switching and substitution, and international interchangeability practices should be brought into line, delegates at Medicines for Europe’s recent biosimilars conference heard.

International Biosimilars

Further Brexit Delay Avoids No-Deal Impact For Pharma – For Now

The EU has given the UK another extension, this time until 31 October, to find a solution to the Brexit impasse. In the meantime, things will stay pretty much as they are for the life sciences sector, although the possibility of a no-deal exit remains if a withdrawal agreement cannot be ratified. 
Brexit Regulation
See All
Advertisement
UsernamePublicRestriction

Register